Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence based laparoscopic and endoscopic training.
Flawless balance sheet and slightly overvalued.
Share Price & News
How has Surgical Science Sweden's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
SE Medical Equipment
1 Year Return
SE Medical Equipment
Return vs Industry: SUS exceeded the Swedish Medical Equipment industry which returned 34.2% over the past year.
Return vs Market: SUS exceeded the Swedish Market which returned 9.6% over the past year.
Price Volatility Vs. Market
How volatile is Surgical Science Sweden's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StWhat Percentage Of Surgical Science Sweden AB (publ) (STO:SUS) Shares Do Insiders Own?
2 months ago | Simply Wall StLooking At Surgical Science Sweden AB (publ) (STO:SUS) From All Angles
3 months ago | Simply Wall StIs Surgical Science Sweden AB (publ) (STO:SUS) Potentially Undervalued?
Is Surgical Science Sweden undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Undervalued: SUS (SEK339) is trading below our estimate of fair value (SEK611.33)
Significantly Undervalued: SUS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: SUS is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: SUS is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate SUS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SUS is overvalued based on its PB Ratio (22.8x) compared to the SE Medical Equipment industry average (4.4x).
How is Surgical Science Sweden forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SUS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SUS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SUS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SUS's revenue (41.6% per year) is forecast to grow faster than the Swedish market (4.5% per year).
High Growth Revenue: SUS's revenue (41.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: SUS's Return on Equity is forecast to be low in 3 years time (13.4%).
How has Surgical Science Sweden performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: SUS is unprofitable, and losses have increased over the past 5 years at a rate of -38.9% per year.
Accelerating Growth: Unable to compare SUS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SUS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17.3%).
Return on Equity
High ROE: SUS has a negative Return on Equity (-6.78%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: SUS is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: SUS is currently unprofitable, so its Return on Capital Employed is negative.
How is Surgical Science Sweden's financial position?
Financial Position Analysis
Short Term Liabilities: SUS's short term assets (SEK57.6M) exceeds its short term liabilities (SEK19.6M)
Long Term Liabilities: SUS's short term assets (57.6M) exceeds its long term liabilities (7.4M)
Debt to Equity History and Analysis
Debt Level: SUS is debt free.
Reducing Debt: SUS had no debt 5 years ago.
Inventory Level: SUS has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if SUS's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable SUS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: SUS is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 39.8% per year.
What is Surgical Science Sweden's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate SUS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate SUS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if SUS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SUS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SUS's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
What is the CEO of Surgical Science Sweden's salary, the management and board of directors tenure and is there insider trading?
Average board tenure
Gisli Hennermark 0
Mr. Gisli Hennermark serves as Chief Executive Officer of Surgical Science Sweden AB (publ) since 2015. He received MSc from Stockholm School of Economics and Cornell University. He worked previously as a ...
Board Age and Tenure
Experienced Board: SUS's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Co-Founder & CTO
- Tenure: 0yrs
Chief Executive Officer
- Tenure: 4.8yrs
Anna Ahlberg (49yo)
Chief Financial Officer
- Tenure: 1.8yrs
Jan Pedersen (54yo)
Director of Global Accounts
- Tenure: 0yrs
Director of Global Sales
- Tenure: 0yrs
Roland Bengtsson (64yo)
Chairman of the Board
- Tenure: 2.8yrs
Jan Bengtsson (75yo)
- Tenure: 14.8yrs
Thomas Eklund (52yo)
- Tenure: 2.8yrs
Nils Sellbom (60yo)
- Tenure: 7.8yrs
Tommy Forsell (66yo)
- Tenure: 0.8yrs
Surgical Science Sweden AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Surgical Science Sweden AB (publ)
- Ticker: SUS
- Exchange: OM
- Founded: 1999
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr2.280b
- Shares outstanding: 6.72m
- Website: https://www.surgicalscience.com
- Surgical Science Sweden AB (publ)
- Drakegatan 7 A, 3 tr.
- Västra Götaland County
- 412 50
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SUS||OM (OMX Nordic Exchange Stockholm)||Yes||Share Capital||SE||SEK||Jun 2017|
Surgical Science Sweden AB (publ) develops and markets virtual reality (VR) simulators for evidence based laparoscopic and endoscopic training. It offers LapSim training system comprising LapSim essence, a ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/10/15 22:07|
|End of Day Share Price||2019/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.